Compare AMLX & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMLX | ECAT |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | 2021 |
| Metric | AMLX | ECAT |
|---|---|---|
| Price | $13.90 | $13.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $20.11 | N/A |
| AVG Volume (30 Days) | ★ 867.2K | 590.3K |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.20% |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.32 |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $3.11 | $13.35 |
| 52 Week High | $17.49 | $17.14 |
| Indicator | AMLX | ECAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 35.37 |
| Support Level | $13.36 | $13.37 |
| Resistance Level | $15.37 | $16.64 |
| Average True Range (ATR) | 0.74 | 0.26 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 48.17 | 14.29 |
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.